Fritextsökning
Innehållstyper
-
Novo Nordisk appoints Mike Doustdar as new CEO
The Danish pharmaceutical giant Novo Nordisk has appointed Mike Doustdar as its new CEO. At the same time, the company announced it was lowering its forecasts –...
-
BMS and venture capital giant form new company
The American pharmaceutical company Bristol Myers Squibb, together with the venture capital firm Bain Capital, is forming a new biotech company. The company wil...
-
It couldn’t be simpler
AI-assisted ZEISS Solution inspects implant coatings automatically.
-
ZEISS Microscope has been Optimized for Capturing Subcellular Structures and their Dynamics
Live imaging with uniform super-resolution in all spatial dimensions.
-
Rapid development in blood analysis – “Sweden is leading the race”
Thousands of analytical tests using just one single drop of blood. What was revealed as a hoax just a few years ago is now a reality, according to KTH professor...
-
Elevating 3D characterization with enhanced performance and efficiencies
Introducing the ZEISS VersaXRM 730 3D X-ray microscope.
-
Quality Assurance for the Highest Medical Standards
Metrology Solutions for Medical Components.
-
FDA inför AI internt efter lyckat pilottest
Från den 30 juni ska samtliga enheter inom FDA använda AI internt. Det meddelar den amerikanska läkemedelsmyndigheten efter att en första pilotstudie precis avslutats.
-
The top five most expensive drugs in 2025
New advanced therapeutic medicines are reaching the market, but their price tags remain exceptionally high. This year’s ranking of the most expensive drugs in t...
-
BioArctic moves forward with its candidate for Parkinson’s
BioArctic announces positive early phase study results for its drug candidate for Parkinson’s disease.
-
Medivir CEO on upcoming study: ”It's about working together with others”
Medivir is a small company with a big task: to take its drug candidate, via extensive clinical studies, all the way to a patient group that currently lacks appr...
-
New ATMP center inaugurated: “In the future, we will see cell and gene therapies in all clinics”
Karolinska Institutet and Karolinska University Hospital’s new ATMP center was inaugurated in Flemingsberg, south of Stockholm. “The ATMP Center is not just a p...
-
Mavatar AB
-
The Top 10 Challenges Facing Laboratories Today
Navigating the Laboratory Automation Landscape
-
AI automates testing of implant coatings
The medical technology group Smith+Nephew uses an AI-supported light microscope ZEISS Axio Imager to inspect coated implants.
-
JMP Statistical Discovery
-
How the Foreign Office will promote Swedish life science exports
The broadness and innovative strength keep Swedish life science exports strong, but the protectionist tendencies in the world are worrying, says Camilla Melland...
-
Ingrid Lönnstedt: Demystification of the power of a scientific study
”You surely do realize that even the smallest changes in study assumptions may influence the estimated sample size needed. And how is it even possible to guess ...
-
Multiplex immunofluorescence chemistries with ZEISS tissue multiplexing workflow
Bringing leading multiplex immunofluorescence chemistries together in one automated 8-channel imaging platform.
-
Abbvie förvärvar lovande projekt inom psykisk ohälsa
Abbvie köper ett läkemedelsprogram inom mental hälsa i en miljardaffär som ser lite annorlunda än vad som tidigare uppgetts.
-
Superconductor technology: Contactless working in the laboratory of the future
Automated filling and weighing of freeze-dry containers in the cleanroom with SupraMotion from Festo
-
Xbrane enters licensing agreement with Indian generics giant
Swedish biosimilar developer Xbrane Biopharma and the Indian company Intas Pharmaceuticals have entered into a license and co-development agreement.
-
Come see us at the upcoming events!
We have some upcoming events where you can see our latest products live!
-
Large study: The benefits and risks of obesity medications
Medications such as Ozempic can reduce the risk of a range of different diseases and health conditions but also increase the risk of others. This is according t...